Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Dose-exploring, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Safety and Immunogenicity of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

NCT05373472 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.

NCT NCT05373472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05373472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Dose-exploring, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Safety and Immunogenicity of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
Lead sponsor
CanSino Biologics Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 6, 2022
Completion date
September 21, 2022
Enrollment
150 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19